Genomes and Genes
Affiliation: Institute of Cancer Research
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsZ Kote-Jarai
Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
Br J Cancer 105:1230-4. 2011..We previously estimated that about 2% of PrCa cases diagnosed ≤ 55 years harbour a BRCA2 mutation and PrCa among BRCA2 carriers has been shown to be more aggressive, with poorer survival...
- A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancerZ Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
Br J Cancer 100:426-30. 2009....
- Mutation analysis of the MSMB gene in familial prostate cancerZ Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Br J Cancer 102:414-8. 2010..The MSMB protein is underexpressed in PrCa and it was previously proposed to be an independent marker for the recurrence of cancer after radical prostatectomy...
- Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcriptZ Kote-Jarai
The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Hum Genet 129:687-94. 2011..Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk...
- Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damageZsofia Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Clin Cancer Res 12:3896-901. 2006..We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells...
- BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trialZsofia Kote-Jarai
Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Cancer Lett 247:259-65. 2007..03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR...
- Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier statusZsofia Kote-Jarai
Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Clin Cancer Res 10:958-63. 2004..The impact of the presence of a germ-line BRCA1 mutation on gene expression in normal breast fibroblasts after radiation-induced DNA damage has been investigated...
- Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
Nat Genet 40:316-21. 2008..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
- Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controlsImogen Locke
The Institute of Cancer Research, London, UK
Cancer Epidemiol Biomarkers Prev 15:1399-402. 2006..Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development...
- Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 geneStephen M Edwards
Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Am J Hum Genet 72:1-12. 2003..These results confirm that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives...
- Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arraysSameer Jhavar
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK
J Mol Diagn 10:50-7. 2008..These studies demonstrate that expression analyses using exon arrays represent a valuable approach for detecting ETS gene translocation in prostate cancer, in parallel with analyses of gene expression profiles...
- Overexpression of RAD51 occurs in aggressive prostatic cancerAnita Mitra
Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Histopathology 55:696-704. 2009..To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes...
- Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controlsImogen Locke
Translational Cancer Genetics Team, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Breast Cancer Res 9:R20. 2007....
- Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyZsofia Kote-Jarai
The Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 43:785-91. 2011..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyRosalind A Eeles
The Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 41:1116-21. 2009..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
- Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL ConsortiumZsofia Kote-Jarai
Section of Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
Cancer Epidemiol Biomarkers Prev 17:2052-61. 2008..This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction...
- Identification of new genetic risk factors for prostate cancerMichelle Guy
Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Asian J Androl 11:49-55. 2009..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
- Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemiaMartin Yuille
Academic Department of Haematology and Cytogenetics, and the Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Blood 99:4216-8. 2002..8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL...
- Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancerSameer Jhavar
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK
BJU Int 103:1256-69. 2009....
- Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibilityJulian Barwell
Clinical Genetics, St George s University of London, United Kingdom
Int J Cancer 121:1631-6. 2007..Our results show a demonstrable impairment in irradiation induced DNA repair in women with heterozygous germline BRCA1 and BRCA2 mutations prior to being diagnosed with breast cancer...
- Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriersLuna Kadouri
Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
Int J Cancer 108:399-403. 2004..Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers...
- Multiple loci with different cancer specificities within the 8q24 gene desertMaya Ghoussaini
Cancer Research UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, CB1 8RN, Cambridge, UK
J Natl Cancer Inst 100:962-6. 2008..We conclude that there are at least five separate functional variants in this region...